NASDAQ:SMMT

Summit Therapeutics (SMMT) Stock Forecast, Price & News

$1.65

+0.10 (+6.45%)

(As of 05/26/2023 ET)

Compare

Today's Range: $1.58
▼
$1.67
50-Day Range: $1.32
▼
$2.17
52-Week Range: $0.66
▼
$5.78

Volume: 803,264 shs
Average Volume: 1.82 million shs
Market Capitalization: $1.15 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Summit Therapeutics MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.75% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.70
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$412.29 M Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.40 out of 5 stars

Medical Sector

937th out of 1,018 stocks

Pharmaceutical Preparations Industry

471st out of 498 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Summit Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
0.75% of the outstanding shares of Summit Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Summit Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Summit Therapeutics has recently increased by 2.76%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Summit Therapeutics does not currently pay a dividend.
Dividend Growth
Summit Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SMMT.

2.1

News and Social Media Coverage

News Sentiment
Summit Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Summit Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 30 people have searched for SMMT on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Summit Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $412,292,984.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
83.70% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 1.59% of the stock of Summit Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Summit Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Summit Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Summit Therapeutics has a P/B Ratio of 8.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Summit Therapeutics (NASDAQ:SMMT) Stock

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMMT Stock News Headlines

May 26, 2023 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Trading Down 5.9%

May 26, 2023 | americanbankingnews.com

Traders Buy High Volume of Summit Therapeutics Call Options (NASDAQ:SMMT)

May 27, 2023 | Legacy Research (Affiliate) (Ad)

Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast

He predicted the 2020 crash a month before it happened… He predicted this year’s collapse back in January…

May 22, 2023 | finance.yahoo.com

11 Stocks with Heavy Insider Buying in 2023

May 18, 2023 | finance.yahoo.com

After buying recently, Summit Therapeutics Inc. (NASDAQ:SMMT) insiders must be dismayed to see the company's market cap drop to US$1.2b

May 18, 2023 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $1.83

May 16, 2023 | finance.yahoo.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2023 Earnings Call Transcript

May 16, 2023 | finance.yahoo.com

Why Shares of Summit Therapeutics Slumped on Tuesday

May 27, 2023 | Stansberry Research (Ad)

Why 2023 Could Kick Off a "Cash Frenzy" in Stocks

But the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.

May 13, 2023 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Downgraded by StockNews.com to "Sell"

May 12, 2023 | finance.yahoo.com

Q1 2023 Summit Therapeutics Inc Earnings Call

May 11, 2023 | seekingalpha.com

Summit Therapeutics, Inc. (SMMT) Q1 2023 Earnings Call Transcript

May 11, 2023 | finance.yahoo.com

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

May 11, 2023 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $1.94

April 13, 2023 | seekingalpha.com

Summit Therapeutics: Another Billionaire Project That Isn't Going Anywhere

April 12, 2023 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Shares Up 6%

April 8, 2023 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $1.57

March 23, 2023 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 8.6%

March 21, 2023 | businesswire.com

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm

March 21, 2023 | reuters.com

SMMT.O

March 13, 2023 | insidermonkey.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2022 Earnings Call Transcript

March 9, 2023 | finance.yahoo.com

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022

March 3, 2023 | finance.yahoo.com

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering

February 1, 2023 | finance.yahoo.com

Bullish insiders bet US$97m on Summit Therapeutics Inc. (NASDAQ:SMMT)

January 30, 2023 | finance.yahoo.com

Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million

January 20, 2023 | msn.com

Summit closes license deal for antibody therapy for cancer; $500M rights offering on track

January 5, 2023 | finance.yahoo.com

We Think Summit Therapeutics (NASDAQ:SMMT) Can Afford To Drive Business Growth

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMMT Company Calendar

Last Earnings: 3/09/2023
Today: 5/27/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SMMT
CUSIP: N/A
CIK: 1599298
Web: www.summitplc.com
Phone: 650-460-8308
Fax: 44-12-3544-3999
Employees: 105
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-78,780,000.00
Net Margins: -1,012.41%
Pretax Margin: -17,289.16%
Return on Equity: -70.92%
Return on Assets: -26.95%

Debt

Debt-to-Equity Ratio: 0.75
Current Ratio: 14.22
Quick Ratio: 14.22

Sales & Book Value

Annual Sales: $700,000.00
Price / Sales: 1,644.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.19 per share
Price / Book: 8.68

Miscellaneous

Outstanding Shares: 697,680,000
Free Float: 113,723,000
Market Cap: $1.15 billion
Optionable: Optionable
Beta: -1.02

Key Executives

Mr. Robert W. Duggan (Age 79)
CEO & Exec. Chairman

Dr. Mahkam Zanganeh D.D.S. (Age 53)
M.B.A., MBA, Co-CEO, Pres & Director
Comp: $651.45k

Dr. Urte Gayko Ph.D. (Age 52)
Head of Regulatory Affairs, Quality Assurance & Safety and Director
Comp: $7.76k

Prof. Dame Kay Davies DBE (Age 72)
FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor

Mr. Ankur Dhingra (Age 47)
Chief Financial Officer

Ms. Michelle Avery
Director of Investor Relations

Dr. Elaine Carla Stracker J.D. (Age 62)
Ph.D., Head of Compliance? & Gen. Counsel

Mr. Campbell Hair
Head of HR?

Dr. Anne Heatherington
Head of Clinical Devel. and Quantitative Sciences

Ms. Divya Chari (Age 55)
Head of Global Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SMMT Stock - Frequently Asked Questions

How have SMMT shares performed in 2023?: Summit Therapeutics' stock was trading at $4.25 on January 1st, 2023. Since then, SMMT shares have decreased by 61.2% and is now trading at $1.65.
View the best growth stocks for 2023 here.
When is Summit Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our SMMT earnings forecast.
How were Summit Therapeutics' earnings last quarter?: Summit Therapeutics Inc. (NASDAQ:SMMT) issued its earnings results on Thursday, March, 9th. The company reported ($0.07) earnings per share for the quarter. The business had revenue of $1.13 million for the quarter. Summit Therapeutics had a negative trailing twelve-month return on equity of 70.92% and a negative net margin of 1,012.41%.
What ETFs hold Summit Therapeutics' stock?: ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB),
What other stocks do shareholders of Summit Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP).
When did Summit Therapeutics IPO?: (SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

What is Summit Therapeutics' stock symbol?: Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."
Who are Summit Therapeutics' major shareholders?: Summit Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (0.90%), BlackRock Inc. (0.26%), Geode Capital Management LLC (0.16%), Steward Partners Investment Advisory LLC (0.09%), Two Sigma Investments LP (0.07%) and HRT Financial LP (0.06%). Insiders that own company stock include Ankur Dhingra, David Jonathan Powell, Mahkam Zanganeh, Maky Zanganeh and Robert W Duggan.
View institutional ownership trends.
How do I buy shares of Summit Therapeutics?: Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Summit Therapeutics' stock price today?: One share of SMMT stock can currently be purchased for approximately $1.65.
How much money does Summit Therapeutics make?: Summit Therapeutics (NASDAQ:SMMT) has a market capitalization of $1.15 billion and generates $700,000.00 in revenue each year. The company earns $-78,780,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.
How many employees does Summit Therapeutics have?: The company employs 105 workers across the globe.
How can I contact Summit Therapeutics?: Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The official website for the company is www.summitplc.com. The company can be reached via phone at 650-460-8308, via email at investors@summitplc.com, or via fax at 44-12-3544-3999.

This page (NASDAQ:SMMT) was last updated on 5/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial